COVID-19 rapid guideline: delivery of systemic anticancer treatments - guidance (NG161)

The purpose of this guideline is to enable services to match the capacity for cancer treatment to patient needs if services become limited due to COVID-19 pandemic.

Source:

National Institute for Health and Care Excellence